Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia

Phase 4

Terminated

• Conditions: Critical Limb Ischemia; Ischemia; Arterial Occlusive Disease; Pain
• Interventions: Drug: placebo; Drug: pregabalin

• Registration Number: NCT00403780
• Lead Sponsor: Karolinska Institutet

Brief Summary

The hypothesis behind the trial is the concept that Pregabalin is effective in reducing pain at rest in lower limb ischemia, and the study evaluates active treatment or placebo added to the regular pain regimens for these patients.

Detailed Description

Critical limb ischemia (CLI) is the end stage of peripheral arterial disease in the legs and is a consequence of deteriorating blood flow supply to the lower limbs. The clinical definition of CLI includes peripheral arterial disease and recurrent rest pain for at least two weeks with or without ulcers or gangrene.

In patients not amenable to revascularization - around 35% - amputation or palliative conservative care remains the options. Pain control is a vital part of any treatment of these patients. Besides being the principal conservative treatment, also patients undergoing revascularization experience severe pain both during work up and after surgery.

Experimental data indicate that pain in CLI is multimodal and to a large extent neuropathic. Still, current therapy is mostly based on opioid treatment, which clinically often affects pain moderately. The doses required to influence pain are also associated to severe side effects. Accordingly, there is a great need to improve pain control in the rather common disease CLI.

comparisons: pregabalin up to 600mg daily in addition to regular pain regimens compared to placebo and regular pain regimens.

Study Timeline

• Study Start: 2006-06
• Study First Submitted: 2006-11-24
• Study First Submitted QC: 2006-11-24
• Study First Posted: 2006-11-27
• Primary Completion: 2013-05
• Study Completion: 2015-07
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-13
• Last Update Posted: 2018-06-15

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• Rest pain, gangrene or ulcers located below the patella for a duration of at least two weeks (either one of these criteria are sufficient).
• One measurement of: Ankle blood pressure(ABP) <70 mm Hg, an toe blood pressure(TBP) <50, or a TcPO2<45 mm Hg, or an ankle/brachial pressure index <0.7 (either one of these criteria are sufficient).
• Informed consent obtained

Exclusion Criteria

• Age < 55 years
• Women of childbearing potential
• Patients already medicating with Pregabalin or Gabapentin
• Creatinine clearance <30ml/min
• Amputation necessary within two weeks
• Revascularization necessary within two weeks (open vascular surgery or endovascular)
• A medical history of clear dizziness
• NYHA class IV heart failure
• Known hypotension, or having a systolic arm blood pressure <120 mm Hg (two consecutive measurements with the patient lying supine)
• Simultaneous or previous (within 30 days prior to study entry participation in a clinical study using experimental drugs or devices
• Mental condition making the subject unable to understand the concepts and risk of the study
• Known allergies against pregabalin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B	placebo	placebo arm with capsule Lyrica Placebo
A	pregabalin	Active intervention with pregabalin

Primary Outcome Measures

Name	Time	Method
Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.	1, 2, 4 and 8 weeks after randomization

Secondary Outcome Measures

Name	Time	Method
Safety outcomes and adverse events will be examined and recorded throughout the study. Patient reported dizziness will be recorded separately in the CRF, as well as blood pressure at visits.	up to 8 weeks, as long as patients is in the study.
Improvement in the Short Form 36 (SF-36) parameter "bodily pain".	This parameter will be evaluated at baseline, after seven and 14 days of treatment. Patients continuing in the study will be scored also at 28 and 56 days.
The amount, dose and duration of concomitant pain medication use during study compared to use before study.	2 weeks after randomization

Trial Locations

Locations (3)

Department of Vascular Surgery, Karolinska University Hospital; 🇸🇪 Stockholm, Sweden

Deptartment of Vascular Surgery, Sahlgrenska University Hospital; 🇸🇪 Gothenburg, Sweden

Deptartment of Surgery, South Hospital; 🇸🇪 Stockholm, Sweden